This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (32)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic

Theodor Karamfilov, MD; Helga Konrad, MD; Kerstin Karte, MD; Uwe Wollina, MD

Arch Dermatol. 2000;136:487-490.

Background  Primary focal hyperhidrosis is a common condition that gives rise to functional and emotional problems and may disturb professional and social life. Recently, low-dose intracutaneous injections of botulinum toxin A have been shown to induce a temporary anhidrosis, with relapses occurring usually after 4 to 6 months.

Objective  To evaluate the short- and long-term effectiveness and possible adverse effects of high-dose botulinum toxin therapy in the treatment of axillary hyperhidrosis.

Design  In an open study, patients with focal hyperhidrosis were treated with intracutaneous injections of botulinum toxin A (Botox; Allergan Inc, Irvine, Calif). A total dose of 200 U of botulinum toxin A was used once per axilla. Patients were observed for up to 15 months.

Settings  University medical center.

Patients  Twenty-four patients with axillary hyperhidrosis were treated. Their ages ranged from 19 to 58 years (mean ± SD, 34.8 ± 12.4 years).

Main Outcome Measures  Reduction of sweating as assessed by the Minor iodine-starch test and planimetry of hyperhidrotic areas. Patients were interviewed at the end of follow-up about their satisfaction with this treatment.

Results  Within 6 days, all patients reported cessation of excessive sweating. The mean ± SD area of excessive sweating identified by the Minor iodine-starch test decreased from 19.27 ± 11.95 cm² to 0.25 ± 0.61 cm² (P<.001). The mean follow-up was 10.0 ± 2.8 months (range, 5-15 months). Four patients (17%) reported a return of axillary hyperhidrosis after 7 to 10 months. All patients who experienced relapse showed an excellent response to a second treatment. The only adverse effects reported were temporary pain and burning during the injections. No muscular weakness, insensitivity, or systemic reactions were observed.

Conclusions  High-dose botulinum toxin A seems to be as safe as low-dose botulinum toxin A in the treatment of axillary hyperhidrosis. The preliminary data suggest a lower rate of relapse.

From the Department of Dermatology, the Friedrich Schiller University of Jena, Jena, Germany.

RELATED ARTICLES

Botulinum Toxin: Beyond Cosmesis
Arnold W. Klein and Richard G. Glogau
Arch Dermatol. 2000;136(4):539-541.
EXTRACT | FULL TEXT  

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2000;136(4):568-569.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low-Dose Efficacy of Botulinum Toxin A for Axillary Hyperhidrosis: A Randomized, Side-By-Side, Open-Label Study
Heckmann et al.
Arch Dermatol 2005;141:1255-1259.
ABSTRACT | FULL TEXT  

Experiences in Thoracoscopic Sympathectomy for Axillary Hyperhidrosis and Osmidrosis: Focusing on the Extent of Sympathectomy
Hsu et al.
Arch Surg 2001;136:1115-1117.
ABSTRACT | FULL TEXT  

Evaluation of Therapeutic Success of Hyperhidrosis Therapy
Heckmann et al.
Arch Dermatol 2001;137:94-94.
FULL TEXT  

High-Dose Botulinum Toxin Type A for Axillary Hyperhidrosis
Schnider et al.
Arch Dermatol 2000;136:1567-1567.
FULL TEXT  

Botulinum Toxin: Beyond Cosmesis
Klein and Glogau
Arch Dermatol 2000;136:539-541.
FULL TEXT